Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial.

ABSTRACT:

Background

Despite the promising therapeutic effects of psilocybin, its efficacy in preventing relapse after withdrawal treatment for alcohol use disorder (AUD) remains unknown. This study aims to assess whether a single dose of psilocybin combined with brief psychotherapy could reduce relapse rates and alcohol use in AUD patients.

Methods

This single-center, double-blind, randomized clinical trial was conducted in Switzerland. We recruited participants with AUD between June 8, 2020, and August 16, 2023 who completed withdrawal treatment within six weeks prior to enrollment. Participants were randomized (1:1) to receive either a single oral dose of psilocybin (25 mg) or placebo (mannitol), combined with brief psychotherapy. The primary outcomes were abstinence and mean alcoh

SUBMITTER: Rieser NM 

PROVIDER: S-EPMC11937691 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature